After HRSA Notification, NACHC Refiles 340B Dispute Complaints Against Drug Manufacturers

Community health centers split their 340B dispute resolution petition against drug manufacturers Eli Lilly, Sanofi, and AstraZeneca into two—one against Lilly alone, the other against Sanofi and AstraZeneca together.

Community health centers on Tuesday split their 340B dispute resolution petition against drug manufacturers Eli Lilly, Sanofi, and AstraZeneca into two—one against Lilly alone, the other against Sanofi and AstraZeneca together—to let federal officials commence proceedings against Sanofi and AstraZeneca.

Read More »

Feds Are “Trying to Muscle” Pharma on 340B Contract Pharmacy, Manufacturer Says in Legal Brief

United Therapeutics (UT) says federal health officials are “trying to muscle an obligation” on drug manufacturers to honor 340B contract pharmacy arrangements “that simply is not there."

Federal health officials are “trying to muscle an obligation” on drug manufacturers to honor 340B contract pharmacy arrangements “that simply is not there,” United Therapeutics (UT) said Tuesday in papers filed in federal district court in Washington, D.C.

Nothing in

Read More »

Medicare Trustees Say Part B Drug Payments Will More than Double by 2030

The Medicare Board of Trustees expects Part B reimbursement for physician-administered drugs will more than double to $46.2 billion by 2030.

Medicare Part B reimbursement for physician-administered drugs is projected to rise from $18.7 billion in 2020 to $21.7 billion this year, and then to more than double to $46.2 billion by 2030, the Medicare Board of Trustees reported to Congress

Read More »

In Hurricane Ida’s Wake, HRSA Announces 340B Registration Flexibility in Louisiana and Mississippi

In light of Hurricane Ida, Louisiana and Mississippi health care providers eligible to participate in the 340B program may enroll immediately rather than having to wait until the next quarterly registration period Oct. 1 through 15.

Louisiana and Mississippi health care providers eligible to participate in the 340B program may enroll immediately rather than having to wait until the next quarterly registration period Oct. 1 through 15, the U.S. Health Resources and Services Administration (HRSA) announced

Read More »

Merck Due to Impose 340B Pricing Policy Changes Tomorrow

Drug manufacturer Merck is scheduled tomorrow to impose restrictions on 340B discounts when entities use contract pharmacies to dispense drugs to patients.

340B hospitals are bracing for a blow tomorrow when drug manufacturer Merck imposes restrictions on 340B discounts when hospitals use contract pharmacies to dispense drugs to patients.

Merck’s 340B contract pharmacy limitations will come on the heels of Boehringer Ingelheim’s

Read More »

HRSA Veteran Herzog to Oversee 340B Program as Agency Begins Search for New OPA Director

Michelle Herzog, the new acting director of HRSA's 340B drug pricing program, speaks at the 2015 340B Coalition summer conference.

Michelle Herzog, long-time second-in-command at the U.S Health Resources and Services Administration’s Office of Pharmacy Affairs (OPA), has taken charge as OPA director on an acting basis.

A HRSA spokesperson confirmed yesterday morning that Herzog will oversee OPA temporarily now

Read More »

Breaking News

News Alert: Becerra Signs off on HRSA Reorganization that Elevates 340B Program’s Status

HHS Secretary Xavier Becerra has signed off on a reorganization of HRSA that elevates decision making about the 340B program closer to the top of the department.

The 340B drug pricing program has a new, higher profile home within the U.S. Health Resources and Services Administration (HRSA), and likely is getting a new director due to its current director’s promotion.

U.S. Health and Human Services (HHS) Secretary

Read More »

Health Centers Plan to Resubmit 340B Dispute Resolution Petitions

The National Association of Community Health Centers says it intends to resubmit 340B ADR claims against three drug companies. An injunction against ADR proceedings involving one of the companies has kept proceedings against the other two from moving ahead, the federal government said.

The U.S. Health Resources and Service Administration (HRSA) early this month invited community health centers to “resubmit a new” 340B administrative dispute resolution (ADR) petition against drug companies that deny or restrict 340B drug discounts when contract pharmacies are involved,

Read More »

As Frustration Mounts Over 340B Contract Pharmacy Impasse, Arguments in Highly Anticipated AstraZeneca Lawsuit Postponed to Mid-October

Oral arguments previously scheduled for Sept. 14 in drugmaker AstraZeneca’s closely watched 340B contract pharmacy lawsuit against HHS and HRSA have been rescheduled for Oct. 18.

Oral arguments previously scheduled for Sept. 14 in drugmaker AstraZeneca’s 340B contract pharmacy lawsuit against HHS and HRSA have been rescheduled for Oct. 18. The U.S. District Court for the District of Delaware announced the new date for arguments on

Read More »

Hospital Groups Back Feds in United Therapeutics 340B Contract Pharmacy Case

United Therapeutics’ denials of and restrictions on 340B pricing involving contract pharmacies are illegal and jeopardize patient care, six hospital groups have told a federal district judge.

Drug manufacturer United Therapeutics’ (UT) denials of and restrictions on 340B drug discounts when covered entities use contract pharmacies are illegal and jeopardize patient care, six hospital groups have told a federal district judge in Washington, D.C.

The groups—American Hospital

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live